Tocilizumab ELISA Kit

Catalog No.

KDC36901

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human IL6R has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Tocilizumab in the sample competitively binds to the pre-coated protein with biotin-labeled Tocilizumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Tocilizumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Tocilizumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

156.25 - 10,000 ng/mL

Sensitivity

102.35 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	4802.5	1358.4	255.8	4927.2	1288.7	261.6
Standard deviation	367	115	26	557	170	31
CV (%)	7.7	8.5	10.0	11.3	13.2	11.9

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 20% prior to the expiration date under appropriate storage condition.

Alternative Names

Atlizumab, MRA / R-1569 / RHPM-1 / RO-4877533, CAS: 375823-41-9

Background

Tocilizumab is a humanized IgG1 monoclonal antibody to the IL-6 receptor that is used largely as therapy of refractory rheumatoid arthritis and other inflammatory arthritides. Tocilizumab blocks the action of IL-6, which is a key proinflammatory cytokine that mediates a wide spectrum of biologic activities including activation of T cells, differentiation of B cells, induction of acute phase reactants, proliferation of fibroblasts, and damage to cartilage and joints. IL-6 levels are elevated in patients with active rheumatoid arthritis. In controlled trials and open label studies, tocilizumab therapy led to improvements in symptoms and laboratory abnormalities associated with several forms of inflammatory arthritis. Tocilizumab was approved for use in the United States in 2010 and current indications include rheumatoid arthritis, giant cell arteritis and both the polyarticular and systemic forms of juvenile idiopathic arthritis (formerly juvenile rheumatoid arthritis). Tocilizumab is considered a disease modifying antirheumatic drug (DMARD) and improves signs and symptoms of disease and decreases cartilage and tissue destruction.

Hemoadsorption as a Supportive Strategy for Severe Toxicity Associated With Chimeric Antigen Receptor T-Cell Therapy: A Case Series., PMID:40510619

Key indicators for guiding tocilizumab therapy to prevent orbital decompression surgery in hormone-resistant dysthyroid optic neuropathy., PMID:40510358

The clinical toxicity of advanced therapy medicinal products., PMID:40509780

Sarilumab in the treatment of rheumatoid arthritis: future perspectives., PMID:40506803

Pulmonary Aspergillosis: Epidemiology and unresolved diagnostic challenges - insights from a two-year retrospective cohort study in Marseille., PMID:40505837

Unravelling VEXAS syndrome: shedding light on a recently recognised medical condition., PMID:40499953

A rare case report: acute necrotizing encephalopathy and acute fulminant myocarditis., PMID:40495992

Clinical characteristics and treatment of infantile Takayasu arteritis in the Chinese Han population: a single-center study., PMID:40495185

Therapeutic Choices in Systemic Sclerosis-Associated Interstitial Lung Disease, a Survey of 2 International Research Groups., PMID:40489954

Management of Patients With COVID-19 During the Pandemic: A Retrospective Cohort Study From a Tertiary Care Centre in Mumbai, India., PMID:40486438

Minocycline in chronic management of febrile infection-related epilepsy syndrome (FIRES): a case series and literature review of treatment strategies., PMID:40481521

Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial., PMID:40480650

Tumefactive demyelination as the first presentation of MOG ab-associated disease., PMID:40479755

Efficacy of tocilizumab monotherapy after ultrashort glucocorticoid administration to treat giant cell arteritis: three year follow-up., PMID:40478774

[VEXAS Syndrome]., PMID:40476413

Steroid refractory immune-related acute disseminated encephalomyelitis (ADEM) successfully treated with 2nd and 3rd line immunosuppressive therapy., PMID:40473324

[Clinical phenotype and genotype analysis of neuroinflammation, autoinflammation, splenomegaly and anemia syndrome caused by IRAK4 gene variant]., PMID:40468499

Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future., PMID:40463417

[Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report]., PMID:40462437

Baricitinib and Tocilizumab in COVID-19: A Call for Deeper Mechanistic and Methodological Exploration., PMID:40459395

IL-6R blockade combined with immunosuppressants alleviates adult-onset Still's disease through immune remodeling: a mass cytometry study., PMID:40457438

Tocilizumab-Based Treatment of Microvascular Inflammation in Kidney Transplant Recipients: A Retrospective Study., PMID:40454296

The first nationwide epidemiological survey of chronic recurrent multifocal osteomyelitis in Japan., PMID:40445191

Physician Burden and Time Delays in Initiating Immunomodulatory Therapy for Non-infectious Uveitis and Inflammatory Eye Diseases., PMID:40441503

Antibody-mediated Rejection - Treatment Standard., PMID:40440205

Mendelian randomisation and infection: pitfalls and promises., PMID:40435229

Successful treatment with tocilizumab in a case of familial Mediterranean fever with Takayasu arteritis., PMID:40433865

Use of Immune Modulating Agents to Regulate Hyperinflammation in Severe COVID 19: Assessment of Tocilizumab Use in Combination with Steroids., PMID:40432839

Efficacy of Tofacitinib in Takayasu Arteritis Refractory to Biologic DMARDs-A Multicentre Study in Indian Patients., PMID:40432338

New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review., PMID:40430462

Experience of High Tibial Osteotomy for Patients with Rheumatoid Arthritis Treated with Recent Medication: A Case Series., PMID:40429328

Interactions of Probiotics with the Immune Cells of Patients with COVID-19 Pneumonia., PMID:40424990

Tocilizumab prophylaxis in double cord blood transplantation., PMID:40423984

Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation., PMID:40423982

Polyangiitis overlap syndrome is a high-risk clinical phenotype for relapse: case series from the KEIO-vasculitis cohort., PMID:40421732

Anti-MDA5 antibody positive dermatomyositis complicated by interstitial lung disease with an improved outcome: A case report., PMID:40419927

Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders., PMID:40413020

Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study., PMID:40412417

Integrative genome-wide association studies, proteome-wide Mendelian randomization, and single-cell RNA sequencing identify interleukin-6 receptor protein as a therapeutic target in aortic aneurysm., PMID:40409638

Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review., PMID:40406130

Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves' orbitopathy: a systematic review and meta-analysis., PMID:40404973

[Update of clinical management in autoimmune encephalitis-2004]., PMID:40399061

Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Long-term Follow-up and Therapeutic Challenges in a Treatment-Resistant Case., PMID:40398846

Comparative effectiveness of intravenous versus subcutaneous tocilizumab for refractory uveitis: a retrospective analysis., PMID:40398691

Thyroid eye disease in the biologic era: a 40-year paradigm shift in nonsurgical therapeutic strategies., PMID:40397653

[Clinical phenotype and genotype analysis of neuroinflammation, autoinflammation, splenomegaly and anemia syndrome caused by IRAK4 gene variantion]., PMID:40393760

Combined IVIG and High-Dose Systemic Corticosteroids for the Management of Pembrolizumab-Induced Cytokine Release Syndrome in Lung Adenocarcinoma., PMID:40391237

Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis: A Randomized Clinical Trial., PMID:40388166

Evolving therapeutic strategies for severe fever with thrombocytopenia syndrome: from past to future., PMID:40385974

Bilateral Alternate Orbital and Ocular Manifestations in a VEXAS Syndrome Patient., PMID:40384388

Document Download

Tocilizumab ELISA Kit.pdf